The Medical Letter on Drugs and Therapeutics
Daclatasvir (Daklinza) for HCV Genotype 3 Infection
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.

The FDA has approved daclatasvir (Daklinza – BMS), an oral direct-acting antiviral drug, for use with sofosbuvir (Sovaldi)1 for treatment of chronic hepatitis C virus (HCV) genotype 3 infection. Daclatasvir is the first drug approved for this indication that does not require the addition of interferon or ribavirin. It is approved in Japan and Europe in combination with other drugs for treatment of HCV genotypes 1-4.

GENOTYPE 3 — HCV genotype 3 is responsible for <10% of HCV cases in the US. It is the predominant genotype in South Asian countries such as India and Pakistan and is responsible for >25% of HCV cases in Central Asia, Australasia, eastern Europe, and tropical Latin America.2 It has been associated with higher rates of steatosis, cirrhosis, and hepatocellular carcinoma than other HCV ... more      

The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App for iOS, Android, and Kindle Fire
  • FREE online per issue CME/CE
Purchase this article:
Title: Daclatasvir (Daklinza) for HCV Genotype 3 Infection
Article code: 1479c
 Electronic, downloadable article - $45
Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.
Recommend to your librarian